Daiwa Securities Group Inc. Boosts Holdings in Repligen Co. (NASDAQ:RGEN)

Daiwa Securities Group Inc. lifted its position in shares of Repligen Co. (NASDAQ:RGEN) by 3.1% during the fourth quarter, HoldingsChannel reports. The firm owned 3,300 shares of the biotechnology company’s stock after purchasing an additional 100 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Repligen were worth $593,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Slow Capital Inc. boosted its position in Repligen by 1.9% in the 4th quarter. Slow Capital Inc. now owns 14,259 shares of the biotechnology company’s stock valued at $2,564,000 after buying an additional 267 shares during the last quarter. Avior Wealth Management LLC grew its stake in Repligen by 22.1% during the 4th quarter. Avior Wealth Management LLC now owns 2,123 shares of the biotechnology company’s stock valued at $382,000 after purchasing an additional 384 shares in the last quarter. Wealth Alliance increased its holdings in Repligen by 16.6% during the 4th quarter. Wealth Alliance now owns 1,941 shares of the biotechnology company’s stock worth $349,000 after purchasing an additional 277 shares during the last quarter. London & Capital Asset Management Ltd raised its position in shares of Repligen by 11.2% in the 4th quarter. London & Capital Asset Management Ltd now owns 61,619 shares of the biotechnology company’s stock valued at $11,079,000 after purchasing an additional 6,215 shares in the last quarter. Finally, Strs Ohio boosted its stake in shares of Repligen by 7.1% during the 4th quarter. Strs Ohio now owns 36,300 shares of the biotechnology company’s stock valued at $6,526,000 after buying an additional 2,400 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on RGEN. KeyCorp lifted their price target on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Stifel Nicolaus boosted their target price on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average target price of $196.70.

Repligen Trading Down 1.3 %

NASDAQ RGEN opened at $165.66 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 7.02. Repligen Co. has a one year low of $110.45 and a one year high of $211.13. The company has a 50-day simple moving average of $185.05 and a 200-day simple moving average of $173.47. The firm has a market capitalization of $9.25 billion, a PE ratio of 230.09, a price-to-earnings-growth ratio of 5.50 and a beta of 1.02.

Repligen (NASDAQ:RGEN) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. The company had revenue of $155.74 million during the quarter, compared to the consensus estimate of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. Repligen’s quarterly revenue was down 16.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.68 earnings per share. On average, equities analysts forecast that Repligen Co. will post 1.46 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO James Bylund sold 4,373 shares of the business’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the transaction, the chief operating officer now owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, COO James Bylund sold 4,373 shares of Repligen stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the sale, the chief operating officer now owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Anthony Hunt sold 16,707 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the transaction, the chief executive officer now owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The disclosure for this sale can be found here. Insiders have sold 25,597 shares of company stock valued at $5,039,532 over the last three months. Company insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.